The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Signatures of early plasticity in the histological transformation of lung cancer.
 
Swanand Rakhade
No Relationships to Disclose
 
Monica F Chen
Stock and Other Ownership Interests - docs; FIGS; Nordisk; Quest Diagnostics
Research Funding - ASCO; NIH
Travel, Accommodations, Expenses - AACR; ASCO
 
Alvaro Quintanal-Villalonga
Honoraria - AstraZeneca
Research Funding - Duality Biologics; Foghorn Therapeutics; Jazz Pharmaceuticals
 
Amin Sabet
No Relationships to Disclose
 
Parvathy Manoj
No Relationships to Disclose
 
Ojasvi Chaudhary
No Relationships to Disclose
 
Tianhao Xu
No Relationships to Disclose
 
Ignas Masilionis
No Relationships to Disclose
 
Christina J. Falcon
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Tal Nawy
No Relationships to Disclose
 
Linas Mazutis
No Relationships to Disclose
 
Ronan Chaligne
No Relationships to Disclose
 
Helena Alexandra Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Taiho Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Dana Pe'er
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Bridge Medicines; D2G Oncology; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Harpoon Therapeutics; Jazz Pharmaceuticals; Kowa; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Joseph Minhow Chan
No Relationships to Disclose